Citadel Advisors’s Franklin Genomic Advancements ETF HELX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.76M | Buy |
63,368
+17,249
| +37% | +$478K | ﹤0.01% | 2795 |
|
|
2025
Q1 | $1.25M | Buy |
46,119
+38,153
| +479% | +$1.03M | ﹤0.01% | 3045 |
|
|
2024
Q4 | $230K | Buy |
+7,966
| New | +$230K | ﹤0.01% | 4762 |
|
|
2024
Q2 | – | Sell |
-11,072
| Closed | -$363K | – | 6294 |
|
|
2024
Q1 | $363K | Buy |
+11,072
| New | +$363K | ﹤0.01% | 4229 |
|